Statement on advancing person-centered, integrated triple elimination responses for HIV, syphilis, and hepatitis B for the United Nations High-Level Meeting on HIV/AIDS

PATH, the International Community of Women living with HIV Eastern Africa, World Hepatitis Alliance, the Global Network of People living with HIV, the International Community of Women living with HIV West Africa, the Coalition of Women living with HIV and AIDS, the International AIDS Society, and Unitaid welcome the UN High-Level Meeting on HIV/AIDS on 22 and 23 June 2026 and global commitment towards ending AIDS as a public health threat.

Despite significant progress, preventable vertical transmission of HIV, syphilis, and hepatitis B virus (HBV) continues to affect women, children, and families worldwide. Stillbirth and childhood mortality rates have stagnated due to fragmented health systems, siloed delivery platforms, and persistent market barriers limiting access to and uptake of elimination of vertical transmission (EVT) services; recent global health financing shifts further threaten this progress. In spite of existing evidence-based approaches and tools, a critical gap remains between what is available and what is accessible, affordable, and equitably delivered to women and newborns who need these services most.

We welcome the Political Declaration’s continued commitment to eliminate vertical transmission of HIV and end pediatric AIDS. However, as countries recalibrate their HIV and broader health responses amidst a shrinking fiscal space, we call on Member States to reinforce their commitments to eliminating HIV, syphilis, and HBV by building inclusive, person-centered triple elimination responses into integrated primary health care platforms. This includes adopting financing, policy, and programmatic interventions that improve the availability and quality of triple elimination services, including:

• accelerating introduction and scale of emerging diagnostic innovations and longer-acting treatment and prevention regimens—including triplex testing for HIV, syphilis, and HBV as well as lenacapavir for greater PrEP choice—while preserving availability of tenofovir disoproxil fumarate for HBV treatment and long-acting HBV therapeutics;
• strengthening inclusive integration of testing, treatment, and prevention for syphilis (and broader sexually transmitted infections) and HBV into antenatal and postnatal care platforms—including provision of hepatitis B birth dose for newborns within 24 hours of delivery;
• embedding communities within EVT planning, implementation, and monitoring processes while investing in community-led organizations as a foundation for health system resiliency; and
• ensuring strong supply chains, data systems, and point-of-care delivery to close gaps in timely screening, treatment, and prevention.

Triple elimination is one of the most cost-effective investments countries can make to protect mothers and future generations, providing a unique opportunity to maximize limited resources by delivering integrated care through a single-entry point. Investing in integrated, community-driven and -owned triple elimination programming embedded within primary health care would enable us to sustainably prevent diseases, improve maternal and child health outcomes, address stigma and discrimination, and reduce health inequities—getting us closer to Universal Health Coverage.

We stand committed to support Member States in advancing the triple elimination agenda and ensuring safe and healthy futures for all mothers and newborns